This is an execution update—not the wet-AMD catalyst investors were awaiting. LUGANO topline data is still expected in August 2026 and LUCIA in Q4 2026, but the filing supplies no Phase 3 efficacy, vision, anatomical, or unmasked safety results. The key near-term expectation was confirmation from LUGANO; this presentation confirms timing rather than delivering that answer. *(DURAVYU in Phase 3 Trials; LUGANO and LUCIA pivotal-program overview)*
| Measure | Earlier standing expectation | What this filing says | Versus expectation |
|---|---|---|---|
| LUGANO wet-AMD Phase 3 topline data | Mid-2026 / beginning mid-year | August 2026 | Timing is now specified, but no data were released *(DURAVYU in Phase 3 Trials)* |
| LUCIA wet-AMD Phase 3 topline data | Second half of 2026 | Q4 2026 | Unchanged in substance *(DURAVYU in Phase 3 Trials)* |
| COMO/CAPRI DME enrollment | Completion expected in Q3 2026 | Fully enrolled in July 2026 | Modestly ahead of the prior timetable *(COMO and CAPRI Phase 3 Program)* |
| DME topline data | Q4 2027 / second half of 2027 | Q4 2027 | Unchanged *(COMO and CAPRI Phase 3 Program)* |
| Cash and investments | $223 million at March 31, 2026; runway into Q4 2027 | $180 million estimated at June 30, 2026; runway still into Q4 2027 | Runway maintained despite a lower cash balance *(Corporate overview)* |
DME enrollment is the real incremental positive. Completing enrollment of both pivotal DME studies in July came before the company’s prior Q3 target. That reduces execution risk around trial recruitment, but it does not pull forward the Q4 2027 data deadline, so it is a modest operational improvement rather than a change in the near-term value-driving timeline. *(COMO and CAPRI Phase 3 Program)*
The cash message meets, rather than improves on, expectations. Cash and investments fell from $223 million at March 31 to an estimated $180 million at June 30—a roughly $43 million quarterly reduction—while management reiterated runway into Q4 2027. Preserving that runway matters because it covers the coming wet-AMD readouts and DME program, but the filing provides no income statement or cash-flow detail to determine whether spending ran better or worse than plan. *(Corporate overview)*
The deck’s supportive clinical material is mostly already-known Phase 1/2 evidence. Management reiterates favorable safety observations across more than 190 patients and prior DAVIO 2/VERONA results, plus continued positive data-monitoring reviews. Those points support the rationale for the pivotal program, but they are not new Phase 3 proof of efficacy; the filing itself notes that conclusive evidence still requires the ongoing controlled trials. *(Safety Profile Across Multiple Clinical Trials; DAVIO 2 Results; Legal Disclaimers)*
Read the original 8-K on SEC EDGAR ↗